XML 10 R4.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Income Statement [Abstract]        
Revenue $ 159 $ 1,498 $ 525 $ 17,953
Cost of sales (64) (3,639) (203) (9,772)
Gross profit 95 (2,141) 322 8,181
Research and development costs (20,544) (20,159) (59,004) (45,806)
General and administrative expenses (5,795) (7,697) (18,610) (21,342)
Restructuring charges 0 0 (1,324) 0
Operating loss (26,244) (29,997) (78,616) (58,967)
Foreign currency gain/(loss), net 1,934 (11,396) (8,448) (11,266)
Other income, net 770 1,412 2,600 3,430
Benefit from R&D credit 2,583 4,486 7,633 9,713
Loss before income tax expense (20,957) (35,495) (76,831) (57,090)
Income tax expense (1) (49) (11) (521)
Net Loss $ (20,958) $ (35,544) $ (76,842) $ (57,611)
Loss per share basic $ (0.15) $ (0.25) $ (0.54) $ (0.42)
Loss per share diluted $ (0.15) $ (0.25) $ (0.54) $ (0.42)
Weighted-average shares outstanding basic 141,701,848 141,198,163 141,692,294 137,775,274
Weighted-average shares outstanding diluted 141,701,848 141,198,163 141,692,294 137,775,274